Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Gilead plans purchase of Kite Pharma to create leader in cell technology

Published 08/28/2017, 03:16 PM
© Reuters.  Gilead plans purchase of Kite Pharma to create leader in cell technology

Investing.com - Shares of Kite Pharma (NASDAQ:KITE)jumped on Monday after Gilead Sciences Inc (NASDAQ:GILD) made an offer to purchase the company for $11.9 billion, or $180 per share, in cash.

Gilead, a biopharmaceutical company, said the purchase of Kite, also a biopharmaceutical company, would create a company that is a global leader in cell technology. Gilead added that the purchase would diversify Gilead’s portfolio and create long-term shareholder value.

Gilead said the transaction is expected to be neutral to earnings by year three and accretive thereafter. If approved, the acquisition should close in the fourth quarter of 2017.

The offer price represents a 29% premium to Kite’s closing value last Friday. Kite investors reacted appropriately, bidding shares up close to the offering price. Monday afternoon, Kite stock was up 28.2% at $178.28. Gilead’s shares had a more muted response and moved up 1.3%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.